Bioarray Genetics awarded patent for breast cancer treatment predictive test

Farmington-based molecular diagnostics company Bioarray Genetics Inc. has received a U.S. patent supporting its lead breast cancer predictive test.

The patent covers methods and kits for predicting the effectiveness of breast cancer treatments. The method also generates a report indicating the likelihood of long-term survival with breast cancer recurrence in the patient.

Read the full article here.